Adma Biologics (ADMA) Stock Falls Amid Market Uptick: What Investors Need to Know

Company Overview - Adma Biologics (ADMA) stock closed at $10.84, reflecting a -1.54% change from the previous day, underperforming compared to the S&P 500's 0.16% gain [1] - The stock has increased by 15.77% over the past month, outperforming the Medical sector's gain of 2.32% and the S&P 500's gain of 3.22% [1] Upcoming Earnings - The upcoming earnings release is highly anticipated, with an expected EPS of $0.08, indicating a 500% growth year-over-year [1] - Revenue is projected to be $87.03 million, representing a 44.75% increase compared to the same quarter last year [1] Analyst Forecasts - Recent revisions to analyst forecasts for Adma Biologics are important, as they reflect short-term business trends and analysts' confidence in the company's performance [2] - The Zacks Consensus EPS estimate has remained unchanged over the past month, with Adma Biologics holding a Zacks Rank of 3 (Hold) [2] Valuation Metrics - Adma Biologics has a Forward P/E ratio of 31.46, which is a premium compared to the industry's average Forward P/E of 21.61 [3] - The Medical - Biomedical and Genetics industry has a Zacks Industry Rank of 90, placing it in the top 36% of over 250 industries [3]